Fig. 4From: Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malariaLogistic regression model for the exposure–response analysis for Day 28 PCR-adjusted ACPR. PK/PD efficacy populationBack to article page